, 
Protocol:CO- 170317095828 -PACT
FINAL 16May2017
1CO-170317095828 -PACT
A RANDOMIZED, DOUBLE -BLIND, PLACEBO -AND 
ACTIVE -CONTROLLED, SINGL E-DOSE, EFFICACY 
AND SAFETY STUDY OF A 
 IN POS TOPERATIVE DENTAL PA IN
Stud y Product Name
Protoco l Number CO-170317095828 -PACT
IND / IDE / EudraCT number Not Applicable
Phase 3
Version and Date FINAL 1 6May2017
This document contains privileged andconfidential information belongin g to the Sponsor. 
Except asotherwise agreed to in writing , by accepting orreviewing thisdocument, you
agree to hold the information contained herein inconfidence and not copy or disclose it to 
others (except where required by  applicable law) or use it for unauthorized purposes. Inthe
event information isdisclosed to others, asrequired byapplicable law,they mustbe informed
that the information is privileged and confidential and may no t be furthe r disclose d by them . 
These restrictions ondisclosures will apply equall y toallfuture information supplied to you
that isindicated as privileged andconfidential.  You agree that nounpublished information 
contained herein will be published or disclosed without the prior writte n approval of 
Sponsor. In the event ofanyactua l orsuspected breach of this oblig ation, Sponsor mustbe 
promptly  notified.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
21. SYNOPSIS
Name of Sponsor/Company:
Johnson & Johnson Consumer , Inc., McNeil Consumer Healthcare Division
7050 Camp Hill Road
Fort Washington, PA 19034
Name of Investigational Product:
Table t
Name of Active Ingredient:
Acetaminophen 
Title of Study: A Randomized, Double -Blind, Placebo- and Active -Controlled, 
Single -Dose, Efficacy  and Safety  Study  of a  in 
Postoperative Dental Pain
Stud y center:
Jean Brown Research
1045 East 3900 South
Salt L ake City , UT   84124
Principal Investigator:
Study period:
Estimated date first subject enrolled: July 
2017
Estimated date last subject completed:
May 2018Phase of development: 3
Objec tives:
To evaluate analgesic onset, efficacy , and safet y of  
compared with 
1000 mg acetaminophen administered as two commercial acetaminophen 500 mg 
caplets (ACM) and 400 mg ibuprofen administered as two commercial ibuprofen 200 
mg liquid -filled capsules (IBU) in the dental pain model following third -molar 
extractions.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
3Meth odology:
This is a single -dose, randomized, double -blind, placebo -and active -contro lled, parallel -
group stud y to evaluate the analgesic onset, efficacy, and safet y profile of  
 compared with two commercial products over a four -hour period after third- molar 
extractions. Subjects will undergo dental extraction of three or fo ur third molars. Maxillary  
third molars may  be removed regardless of impaction level. The mandibular extractions 
must meet one of the following scenarios and must not result in a trauma rating of severe on 
a mild, moderate, or severe scale:
two full bony  impactions
two partial bony  impactions
one full bony  impaction in combination with one partial bony  impaction
Subjects who meet the randomization criteria (post -surgical pain of moderate to severe on 
the four -point categorical pain scale, and at least a sco re of 5 on the 11 -point [0 -10] pain 
intensity  numeric al rating scale [PI -NRS] at baseline within 4.5 hours of last stitch from 
dental extractions) will be assigned to one of four treatment groups.
Approximately  660subjects will receive a single dose of either , ACM 
1000 mg, IBU 400 mg, or placebo in a 4:4:2:1 allocation ratio, and will be stratified 
according to gender and baseline pain rating (moderate or severe). To maintain the double -
blind nature of the stud y, an independent third party will administer study  drug to 
blindfolded subjects. No less than approximately  30% of randomized subjects will be either 
male or female. In addition, no more than approximately  30% of subjects will be 17 y ears of 
age at the tim e of screening .
Self-reporte d pain intensity  will be collected at baseline (time 0). Pain intensity  and pain 
relief will be collected at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, and 4 hours (± 5 minutes) post 
dose as well as at the time of rescue (if applicable) and time of meaningful pa in relief (if 
applicable) . Perceptible pain relief and meaningful pain relief will be collected using two 
separate stopwatches. Subjects who do not experience an y pain relief after dosing will be 
encouraged but not required to wait at least 1 hour before u sing rescue therapy .Subject 
global evaluation of the investigational product will be collected at hour 4,at the time of 
rescue medication ,or at the time of subject withdrawal , whichever comes first, with a 0-4 
categorical rating scale: (0) poor, (1) fai r, (2) good, (3) very good, and (4) excellent.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
4Number of subjects (planned): Approximately  660 subjects
Diagnosis and main criteria for inclusion:
Subjects 17 to 50 y ears of age who meet the inclusion and exclusion criteria, which includes 
surgical extr action of three or four third molars resulting in at least moderate pain and a pain 
intensity  of ≥5 on a 0 to 10 scale , will be eligible for the study .
Investigational product, dosage and mode of administration:
To maintain the double-blind nature of the study , an independent third part y will administer 
a  tablets to blindfolded 
subjects depending on randomization  Subjects will swallow the dose with up to 180 mL  of 
water at ambient temperature .
Duration of treatment: One dose, four hours

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
5Reference treatments, dosage and mode of administration:
Depending on randomization, an independent third party  will administer one of the 
following reference products with up to 180 ml ofwater at ambient temper ature to 
blindfolded subjects:
a single 1000 -mg dose of acetaminophen as two commercial ACM 500 mg caplets ,
a single 400 -mg dose of ibuprofen as two commercial IBU 200 mg liquid -filled 
capsules ,
a single dose of two placebo caplets
Criteria for evaluatio n:
Primary Efficacy Endpoint
Time to confirmed perceptible pain relief (TCPR)
Secondary Efficacy Endpoints
Time to meaningful pain relief (TMPR);
Percentage of subjects with confirmed perceptible pain relief from 30 minutes to 
successively earlier minutes i n one -minute increments (  versus PLACEBO );
Tertiary Efficacy Endpoints :
Percentage of subjects with meaningful pain relief at 35, 40, and 45 minutes (  
versus ACM )
Percentage of subjects with confirmed perceptible relief at 15, 20, and 25 mi nutes
Time weighted sum of pain intensity difference from 0 to 4 hours (SPID 0 -4);
Time weighted sum of pain relief from 0 to 4 hours (TOTPAR 0 -4);
Pain relief (PAR) and pain intensity difference (PID) scores at individual time points;
Time to rescue analg esic (duration of relief after dosing);
Subject Global Evaluation.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
6Safety:
Safety  will be monitored and assessed by  reviewing the collection, evaluation, and anal ysis 
of subject -reported spontaneous adverse events (AEs).
Statistical Methods:
Time to conf irmed perceptible pain relief (TCPR) and time to meaningful pain relief 
(TMPR) will be analy zed using survival data anal ysis. The survival function (cumulative 
proportions of subjects with pain relief at each time point) and the median survival time will 
be estimated b y the Kaplan -Meier method for each treatment. The median survival times for 
the active treatments will be compared using the bootstrap re- sampling method and the 
survival functions of the active treatments will be compared with the survival fu nction of 
placebo using the Wilcoxon test.  The earliest time of separation between  and 
placebo will be established by  comparing the percentage of subjects with confirmed 
perceptible pain relief starting from 30 minutes to successive earlier minut es in one minute 
increments, until statistical significance is no longer achieved. The dichotomized response 
will be anal yzed using logistic regression anal ysis.
2. STUDY FLOWCHART
Table 1: Schedule of Activities
Scree ningBaselin e
(Day of Surgery)Hours
Post-DoseFollow-Up
Call
Procedures Day -30to1 Day1 0 to4hours Day 6(±1day)
Written informed consent and/or assent X
Demography X
Collection of age X
Inclusion /Exclusion assessment X1X
Significant medical history X1X
Vital signs2X1X
Height, weight, andBMI X
Urine pregnancy test3X1X
Urine drug screen11X1X
Serolog y4X

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
7Scree ningBaselin e
(Day of Surgery)Hours
Post-DoseFollow-Up
Call
Procedures Day -30to1 Day1 0 to4hours Day 6(±1day)
Dental extraction surgery X
Categorical andNumerical Pain Intensity X5
Randomization criteria X
Inves tigational product administration X
Stopwatch assessments (pain relief) X
Pain intensity andpain relief rating s6X
Rescue therapy X7
Subject Global Evaluation X8
Prior andConcomitant Therapy X X X X
Safety monitoring X X9X9X9
SubjectDisposition X10
Follo w up interview X
1:Only baseline assessments willbecollected ontheCRF
2:Blood pressure, heart rate, respiratory rate,andoraltemperature
3:Womenofchildbearing potential
4:HIV antibody, hepatitis Bsurface antige n(HBsAg) andhepatitis Cvirus antibody (anti-HCV)
5:Scored within 4.5hoursafter laststitch from dental surgery
6:Subjects willrecord pain ratings onworksheets that will beentered intotheCRF bydesignated sitestaff. Ratings 
will be collected at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, and 4 hours (± 5 minutes) post dose. If a subject requests
rescue medicine, ratings willbecollected before administratio n.Ratings will also be collected at the time of 
meaningful pain relief (if applicable).
7:Subjectswillbeencouraged towaitat least 1 hour after investigational product administration before using rescue
medicine.
8:At Hour 4,at time immediately before use of rescue medication , or at the time of early termination if a subject is      
discontin ued or w ithdrawn earlier than four hours after dosing .
9:Includes collection ofAEs and any report ofpregnancy
10:EndofStudy iswhen all4-Hourassessments arecomplete or at the time of subject w ithdrawal
11:Minimum requirements for urine drug testi ng at screening and on the day of surgery include cocaine, 
tetrahydrocannibinol, opioids (e.g., buprenorphine, oxycodone, methadone, and morphine), be nzodiazepines, and 
amphetamin es

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
8TABLE OF CONTENTS
1. SYNOPSI S ................................ ................................ ................................ ...................2
2. STUDY FLOWCHART ................................ ................................ ...............................6
3. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ............................12
4. ETHI CS................................ ................................ ................................ ......................13
4.1. Institutional Review Board (IRB) / Independent Ethics Committee (I EC)................13
4.2. Ethica l Conduct of the Study ................................ ................................ ......................13
4.3. Subject I nformation and Consent ................................ ................................ ...............13
4.4. Subject Written Assent................................ ................................ ...............................14
5. STUDY ADMINI STRATIVE STRUCTURE ................................ ...........................15
6. INTRODUCTION ................................ ................................ ................................ ......15
7. STUDY OBJECTIVES AND ENDPOINTS ................................ .............................16
7.1. STUDY OBJECTIVES ................................ ................................ ..............................16
7.2. STUDY ENDPOINTS ................................ ................................ ...............................16
7.2.1. Primary  Efficacy  Endpoint ................................ ................................ .........................16
7.2.2. Secondary  Efficacy  Endpoint ................................ ................................ .....................16
7.2.3. Tertiary  Efficacy  Endpoint ................................ ................................ .........................16
7.3. Safety ................................ ................................ ................................ ..........................17
8. INVESTIGATIONAL PLAN ................................ ................................ ....................18
8.1. Overall Study  Design andPlan ................................ ................................ ..................18
8.2. Selection ofStudy Population ................................ ................................ ....................19
8.2.1. Inclusion Criteria ................................ ................................ ................................ ........19
8.2.2. Exclusio n Criteria................................ ................................ ................................ .......20
8.3. Subject Withdrawal Criteria................................ ................................ .......................22
9. INVESTIGAT IONAL PROD UCT MATERIAL S AND MA NAGEMENT.............23
9.1. Investigational Product ................................ ................................ ...............................23
9.2. Description of Study  Product ................................ ................................ .....................23
9.3. Investigation al Product Packaging and Labeling ................................ .......................24
9.4. Investigator Unblinding ................................ ................................ ..............................24
9.5. Method of Assigning Subjects to Treatment Groups ................................ .................24
9.6. Study  Product Storage, Accountability  and Disposal ................................ ................25

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
99.7. Preparation, Dispensing and Administration of Investigational Prod uct...................25
9.8. Product Quality  Complaints ................................ ................................ .......................27
10. STUDY PROCEDURES................................ ................................ ............................28
10.1. Overview ................................ ................................ ................................ ....................28
10.2. Screening Visit ................................ ................................ ................................ ...........28
10.3. Baseline Visit (Day  of Surgery ) ................................ ................................ .................28
10.3.1. Randomization ................................ ................................ ................................ ............29
10.3.2. Postdose Assessments ................................ ................................ ................................29
10.3.3. End of Study ................................ ................................ ................................ ...............30
10.4. F ollow-Up Phone call ................................ ................................ ................................ .30
10.5. Life Sty le Guidelines ................................ ................................ ................................ ..31
10.5.1. Meals and Dietary  Restrictions ................................ ................................ ..................31
10.5.2. Alcohol, Caffeine and Tobacco Consumption / Restrictions ................................ .....31
10.5.3. Physical Activity  Requirements / Restrictions ................................ ...........................31
10.5.4. Contraception for Females ................................ ................................ .........................31
10.5.5. Contraception for Males ................................ ................................ .............................32
10.6. Prior and Concomitant Medications and Therapies ................................ ...................32
10.6.1. Permitted Th erapies ................................ ................................ ................................ ....32
10.6.2. Prohibited Therapies ................................ ................................ ................................ ...32
10.7. Rescue Medicine ................................ ................................ ................................ ........33
11. ASSESSMENTS ................................ ................................ ................................ ........34
11.1. Efficacy  Assessments ................................ ................................ ................................ .34
11.2. Safety  Assessments ................................ ................................ ................................ ....34
11.3. Vital Signs ................................ ................................ ................................ ..................35
12. ADVERSE EVENT REPORTING ................................ ................................ ............36
12.1. Introduction ................................ ................................ ................................ ................36
12.2. Reporting Period ................................ ................................ ................................ .........36
12.3. Definition of an Adverse Event ................................ ................................ ..................36
12.4            Abnormal Test Findings ................................ ................................ .............................37
12.5. Serious Adverse Eve nts (SAE) ................................ ................................ ...................38
12.6 Hospitalization ................................ ................................ ................................ ............38
12.7. Resolution ................................ ................................ ................................ ...................39

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
1012.8. S everity  Assessment ................................ ................................ ................................ ...40
12.9. Causality  Assessment ................................ ................................ ................................ .40
12.10. Exposure I n Utero ................................ ................................ ................................ ......41
12.10.1. Withdrawal Due to Adverse Events ................................ ................................ ...........42
12.10.2. Eliciting Adverse Event Information ................................ ................................ .........42
12.10.3. Reporting Requirements ................................ ................................ .............................42
12.10.3.1.  Serious Adverse Event Reporting Requirements ................................ ........................43
13. STATI STICS ................................ ................................ ................................ ..............45
13.1. Samp le Size Determination ................................ ................................ ........................45
13.2. Analy sis Sets ................................ ................................ ................................ ..............45
13.2.1. Efficacy  Anal ysis Sets ................................ ................................ ................................45
13.2.2. Safety Anal ysis Population ................................ ................................ ........................45
13.2.3. Subject Disposition and Protocol Violations ................................ ..............................45
13.3. Baseline and Demographics ................................ ................................ .......................46
13.4. Previous and Concomitant Medica tions................................ ................................ .....46
13.5. Efficacy  Anal ysis................................ ................................ ................................ .......46
13.6. Statistical Hy pothes es and Treatment Comparisons ................................ ..................47
13.7. Data Computations and Data Imputations ................................ ................................ ..48
13.7.1. Time to Confirmed Perceptible and Meaningful Pain Relief................................ .....48
13.7.2. Endpoints Relating to Pain I ntensit y and Pain Relief ................................ ................48
13.8. Analy sis Methods ................................ ................................ ................................ .......49
13.8.1. Time to Confirmed Perceptible and Meaningful Relief ................................ .............49
13.8.2. Earliest Statistically  Significant Separation of  and Placebo on 
Percentage of Subjects with Confirmed Perceptible Relief ................................ .......49
13.8.3. Percentage of Subjects with Meani ngful Pain Relief at 35, 40, and 45 
minutes ................................ ................................ ................................ .......................49
13.8.4. Percentage of Subjects with Confirmed Perceptible Pain Relief at15, 20, 
and 25 minutes ................................ ................................ ................................ ............49
13.8.5. SPID0-4 and TOTPAR0-4 .........................................................................................49
13.8.6. PID and PAR at each Time ................................ ................................ ........................49
13.8.7. Time to Rescue ................................ ................................ ................................ ...........50
13.8.8. Subject Global Evaluation ................................ ................................ ..........................50
13.8.9. Subgroup Anal yses................................ ................................ ................................ .....50

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
1113.9. Safety  Anal ysis................................ ................................ ................................ ...........50
13.9.1. Adverse Events ................................ ................................ ................................ ...........50
14. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS ................................ ........51
14.1. Study  Monitoring ................................ ................................ ................................ .......51
14.2. Audits and Inspections ................................ ................................ ...............................52
14.3. Institutional Review Board (IRB)/Independent Ethics Committee (I EC)..................52
15. QUALITY CONTROL AND QUALITY ASSURANCE ................................ .........52
16. DATA HANDLING AND RE CORDKEEPING ................................ .......................53
16.1. Case Report Forms/ Electronic Data Record ................................ .............................53
16.2. Record Retention ................................ ................................ ................................ ........53
17. SPONSOR DI SCONTINUA TION CRITERIA ................................ .........................53
18. PUBLICATION POLICY ................................ ................................ ..........................54
19. LIST OF REFERENCES ................................ ................................ ...........................54
20. APPENDI CES ................................ ................................ ................................ ............55
LIST OF TABLES
Table 1: Schedule of Activities ................................ ................................ ................................ ..6
Table 2: Abbreviations and Specialist Terms................................ ................................ ...........12
Table 3: Investigational Product ................................ ................................ ...............................23
Table 4: Sponsor Contact I nformation ................................ ................................ .....................44
Table 5: Order of Tests and Assigned Alpha Values ................................ ...............................47
LIST OF FIGURES
Figure 1: Study  Design ................................ ................................ ................................ ..............19

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
123. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
The following abbreviations and specialist terms are used in this study protocol.
Table 2: Abbreviations and Specialist Terms
Abbreviation/ 
TermDefinition
AE Adverse event
ACM Acetaminophen
BMI BodyMass Index
CRF Case report form
EDC Electronic data capture
EIU Exposure in Utero
IBU Ibuprofen
ICH GCP International Conference on Harmonization Good Clinical Practice
IRB/IEC Institutional Review Board/ Independen t Ethics Committee
NSAID Nonsteroidal anti -inflammatory drug
OTC Over the counter
PAR Pain relief
PI Principle Investigator
PID Pain intensity difference
PQC Product Quality Complaint
PI-NRS Pain intensit y-numerical rating scale
PR-NRS Pain relie f-numerical rating scale
RSI Reference Safe tyInformation
SAE Serious adverse event
SPID Time weighted sum of pain intensity difference
TOTPAR Time weighted total pain relief scores

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
134.ETHICS
4.1. Institutional Review Board (IRB) / Independent Ethics Co mmittee 
(IEC)
It is the responsibility ofthe Investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent forms, and other relevant documents, e.g., 
advertisements, if applicable, from the IRB/IEC.  All correspond ence with the IRB/I EC should 
be retained in the Investigator File (Site Master File).  Copies of IR B/IECapprovals should be 
forwarded to the Sponsor.
The only circumstance in which a protocol amendment may be initiated prior to IRB/I EC 
approval is where t he change is necessary to eliminate apparent immediate hazards to the 
subjects.  In that event, the Investigator must notify theIRB/I ECand the Sponsor in writing 
within 5 working da ys after implementation.
4.2. Ethical Conduct of the Study
The study willbe performed in accordance with the protocol, International Conference on 
Harmonization Good Clinical Practice (GCP) guidelines (ICH E6) and applicable local 
regulatory requirements and laws.
4.3. Subject Information and Consent
Onlysubjects who provide informed consent will continue in the stud y.  All parties will ensure 
protection of subject personal data and will not include subject names or subject initials on any
forms, reports, publications, or in any other disclosures.  Each subject will be assigne d a stud y 
number that is used in the Case Report Form (CRF) in lieu of the subject’s name.  In case of 
data transfer, the Sponsor will maintain high standards of confidentiality  and protection of 
subject personal data.
Theinformed consent form must beagreedtobytheSponsor andtheIRB/I ECandmust be 
in compliance with ICH E6, GCP, local regulatory requirements, and legal requirements.
The Principal Investigato r(PI)must ensure that each study subject isfullyinformed about the 
nature and objectives of the study and possible risks associated with participation.  The 
Investigator, or a person designated by the Investigator, will obtain written informed consent 
from each subject before any study-specific activity is performed.  The informed consent for m 
used in this stud y,andany changes made during the course of the study , must be prospective ly
approved byboth theIRB/IECand the Sponsor before use.  The Investigator will retain the 
original of each subjec t's signed consent form.  A cop y of the signe d and dated consent form 
will be provided to subjects.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
144.4. Subject Written Assent
After the informed consent form is signed and dated by the parents or legally authorized 
representatives and witnessed by a member of the investigator’s clinical team, writt en assent to 
participate in the stud y must be obtained from prospective subjects who are below the age of 
legal consent yet old enough to understand details of the stud y.  During the assent process, the
PIor designee will provide the minor with an assent document that explains, in concrete and 
age-appropriate terms, the purpose of the research, what they will be asked to do and what 
procedures they will underg o.  The assent document will focus on the risks, benefits, and 
alternatives to research participation as well as the confidentiality ofanyinformation obtained 
as a result of their participatio n.  The PI  or designee will explain the information, give the 
minor a chance to ask questions and ask the minor to indi cate their assent by signing the assent 
document.  The prospective subject will do this by signing an IRB/IEC-approved assent form 
or designated assent section of the informed consent, depending on individual institutional 
regulations.  A witness must also sign and date the assent form.  The orig inal signed assent 
form will be retained by the investigator as part of the source documents and will be available 
for review b y the Sponsor.  A cop y of the signed and dated assent form will be given to the 
subject. Assent by the subject acknowledges willingness to participate, but does not 
necessarily constitute an understanding of the procedures and hazards of the stud y.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
155. STUDY ADMINISTRATIVE STRUCTURE
Details on the administrative structure of the stu dy (e.g., Principal Investigator (PI)/study site 
personnel, the Sponsor study team, and the external service providers) will be included in a 
studycontact list.  The study contact list will also include contact information for the Sponsor,
Investigator(s), Monitor(s), Clinical and Bioana lytical Laboratories, and IRB /IECs, as well as 
the names and titles of the person(s) authorized to sign the protocol and the protocol 
amendment(s) for the sponsor. This list will be maintained in the study and site master files 
throughout the stud yfor inclusion in the clin ical study report.
6. INTRODUCTION
Acetaminophen is a par a-aminophenol derivative with analgesic and antipyretic properties , and 
is thought to produce analgesia byinhibiting prostaglandin s ynthesis centrally and elevating the 
pain threshold.  Acetaminophen is available as an ove r-the-counter (OTC) analgesic and 
antipyretic in manyglobal markets. In the US, TYLENO L®is commercial ly available inextra 
strength (500 mg ) and regular strength (325 mg) dosage forms marketed under the Internal 
Analgesic, Antip yretic and Antirheumatic Drug Products for OTC Human Use Tentative Final 
Monograph.  TYLENO L®Regular Strength 325 mg is dosed 2 dosage units every 4 to 6 hours 
and TY LENO L®Extra Strength 500 mg is dosed 2 dosage units every 6 hours. It is labeled for 
the temporary relief of minor aches and pains due to the common cold, headache, backache, 
toothache, premenstrual and menstrual cramps, minor pain of arthritis, muscular aches and f or 
the temporary relief of fever.
The overall purpose of this study is to evalu ate the analgesic onset, efficacy, and safety ofa 
single dose of 1000 mg acetaminophen administered as  tablets 
compared with a single dose of 1000 mg acetaminophen administered as two commercial 
acetaminophen 500 mg caplets ( ACM ), asingle dose of 400 mg ibuprofen administered as two 
commercial ibuprofen 200 mg liquid- filled capsules (IBU), and placebo over 4hours.  
The dental pain model, a validated model of acute pain widely used to
study analgesic efficacy of compounds, will be used in this study  [1, 2].Reference Safet y
Inform ation (RSI) for the  and ACM commercial product is the Drug Facts labeling 
forthe ACM commercial product in the US, andtheRSIfor the IBU commercial product is the 
associated Drug Facts Label in the US.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
167. STUDY OBJECTIVES AND ENDPOINTS
7.1. STUDY OBJEC TIVES
To evaluate analgesic onset, efficacy , and safet y of 1000 mg acetaminophen administered as 
 compared with 1000 mg acetaminophen 
administered as two commercial acetaminophen 500 mg caplets (ACM) and 400 mg ibuprofen 
administered as two commercial ibuprofen 200 mg liquid -filled capsules (IBU) in the dental 
pain model following third -molar extractions.
7.2. STUDY ENDPOINTS
7.2.1. Primary Efficacy Endpoint
Time to confirmed perceptible pain relief
7.2.2. Secondary Efficacy End point
Time to meaningful pain relief
Percentage of subjects with confirmed perceptible relief from 30 minutes to 
successivel y earlier minutes in one -minute increments (  versus 
PLACEBO );
7.2.3. Tertiary Efficacy Endpoint
Percentage of subjects with mean ingful relief at 35, 40, and 45 minutes  versus ACM);
Percentage of subjects with confirmed perceptible relief at 15, 20, and 25 minutes
Time weighted sum of pain intensity  difference from 0 to 4 hours (SPI D 0-4);
Time weighted sum of pain relief from 0 to 4 hours (TOTPAR 0 -4);
Pain relief (PAR) and pain intensity  difference (PID) scores at individual time points;
Time to rescue analgesic (duration of relief after dosing);
Subject Global Evaluation.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
177.3. Safety
Safety  will be monitored and assessed by reviewing the collection, evaluation, and anal ysis of 
subject -reported spontaneous adverse events (AEs).

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
188. INVESTIGATIONAL PLAN
8.1. Overall Study Design andPlan
This is a single -dose, randomized, double -blind, placebo -and active -controlled, parallel -group 
study  to evaluate the analgesic onset, efficacy , and safet y profile of  
compared with two commercial products over a four- hour period after third -molar extractions
(Figure 1).  Subjects will undergo dental extra ction of three or four third molars. Maxillary
third molars may be removed regardless of impaction level.  The mandibular extractions must 
meet one of t he following scenarios and must not result in a trauma rating of severe in a mild, 
moderate, or severe scale:
two full bony impactions
two partial bony impactions
one full bony impaction in combination with one partial bony impaction
Subjects who meet the randomization criteria (post -surgical pain of moderate to severe on the 
four-point categorical pain sca le, and at least a score of 5 on the 1 1-point [0-10] pain intensity
numerical rating scale [P I-NRS] at baseline within 4.5 hours of last stitch from dental 
extractions) will be assigned to one of four treatment groups.  Approximately 660subjects will 
receive a single dose of either , ACM 1000 mg, IBU 400 mg, or placebo in 
a 4:4:2:1 allocation ratio, and will be stratified according to gender and baseline pain rating 
(moderate or severe).  No less than approximately 30% of randomized subject s will be either 
male or female. In addition, no more than approximately  30% of subjects will be 17 y ears of 
age at the time of screening . Self- reported pain intensity will be collected at baseline (time 0).  
Pain intensity and pain relief will be collecte d at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, and 4 hours 
(± 5 minutes) after the dose.  P erceptible pain relief and meaningful pain relief will be collected 
using two separate stopwatches.  Subjects who do not experience a ny pain relief after dosing 
will be e ncouraged, but not required, to wait at least 1 hour before using rescue thera py.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
19Figure 1: Study Design
8.2. Selection ofStudy Population
Thefollowing eligibility criteria aredesigned toselect subj ectsforwhom studytreatment is 
considered appropriate. Allrelevant medical andnonmedical conditions should be conside red
when deciding whether thisprotocol issuitable foraparticular subject. No waivers toinclusion
orexclusion criteria willbepermitted.
8.2.1. Inclusion Criteria
Subjects areeligible forenrollment ifthey:
1. Are 17 to 5 0 yearsofage(inclusive) atthetime ofscreenin g;
2. W eigh 100lbs.orgreater andhave a body mass index (BMI )of 18to30(inclusive) at 
screening;
3. Haveundergone dental extraction ofthree orfour third molars. Maxillar ythird molars may
beremoved regardless ofimpaction level. Supernumerary  teeth may  also be removed. The

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
20mandibular extractions must meet one of thefollowing scenarios (and must notresultina
trauma rating of‘severe’ on a mild, moderate, or severe scale):
twofullbony impactions
twopartial bony impactions
one full bony impaction in combination with one partial bony impaction;
4.   Indicate at least moderate pain on a categorical sca le ranging from (0) none, (1) mild, (2) 
moderate, or (3) severe AND at least a score of 5 on the 11- point (0- 10) pain intensity
numerical rating scale ( PI-NRS) at baseline w ithin 4 .5hours of the last stitch from oral 
surger y;
5.   Are a ble to comprehend a nd follow the requirements of the study (including availability on 
scheduled visit dates) based upon rese arch site personnel’s assessment;
6.   Are able to provide written informed con sent;
7.   Females of childbearing potential and males who are sexually active must be willing to use
a medicall y acceptable method of birth control during the study. In addition, females of 
childbearing potential who are sexually  active must be willing to use a medically  
acceptable method of birth control for up to 30 days af ter the last dose of investigational 
product ;  
8.   Are w illing for this to be the only investigational product used during thestudy.
8.2.2. Exclusion Criteria
Subjects will be excluded if they :
1.   Are female andare pregnant or breastfeeding;
2.   Aremale with a pregnant partner or a partner who is current ly try ing to become pregnant;
3.   Have aknown allergy toacetaminophen or nonsteroidal anti- inflammatory drugs
(NSAIDs ), including aspirin as well as h ypersensitivity  to hydrocodone or other opioids;
4.   Presence or history of major medical condition that in the investigator’s opinion may  
jeopardize the subject’s safe ty orwell-being, or the integrity ofthestudy (e.g. hepatic, 
renal, pancreatic, gastrointestinal, cardiovascular, cerebrovascular , or thyroid diseases as 
well as a history  ofhead injury  or seizure s, history of respiratory  depression or lung 
problems such as but not limited to asthm aor chronic obstructive pulmonary disease ,
psychiatric disorders , problems urinating ,a history o f blockage or narrowing of the 
stomach or intestines , uncontrolled h ypertension indicated as systolic blood pressure ≥160
mm Hg or diastolic blood pressure ≥100 mm Hg , or uncontrolled diabetes in the last 6 
months);

t
Protocol:CO- 170317095828 -PACT
FINAL 16May2017
215.   Are not able to swallow whole large ta blets or capsules;
6.   Routin elyuse oral analgesics ≥5 times per week;
7.   Have ahistor y ofchronic tranquilizer use, hea vy drinking, or substance abuse in the last 5
years.  Heavy drinking is defined as the use of more than 4 standard drinks dailyor more 
than 14 drinks a week for men, and more than 3 standard drinks daily or more than 7 
standard drinks in a week for women.  Standard drink refers to 14 g (0.6 oz .) of pure 
alcohol, which is approximately 12 oz. ofbeer, 8 oz. of malt liquor, 5 oz. of wi ne, 1.5 oz . or 
“shot” of 80- proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey);
8.   Have ahistor yof endoscopically documented peptic ulcer disease or bleeding disorder in 
the last 2 years;
9.  Use d oral OTC or prescription products (e xcept contraceptive medications and those 
required for use during the oral surgical procedure) , vitamins, or herbal supplements within 
5 days or 5 hal f-lives (whichever is longer) before the oral surgical procedure;
10. Use d any immunosuppressive drugs, co rticosteroids (except for topical corticosteroids) , or 
injectable or oral anticoagulants (e.g., heparin, Lovenox, Xarelto, Eliquis, Pradaxa, 
Coumadin, Miradon) within 2 weeks of screenin g;
11. Use dalcohol within 3 day s before the oral surgical procedur e;
12. Have a positive urine drug screen , including a test for buprenorphine . However, if tested 
positive for amphetamine/methamphetamine due to treatment for Attention Deficit 
Hyperactivit yDisorder ,the subject will not be excluded;
13. Consumed meth ylxant hine-containing products (e.g., chocolate bars or chocolate 
beverages, coffee, tea, cola or caffeinated energy drinks), tobacco, or nicotine containing 
products (e.g., cigarettes, cigars, nicotine replacement therapies) <12 hours before the oral 
surgical pro cedure;
14. Use of monoamine oxidase inhibitors within 14 day s prior to surgery ;
15. Has a positive test for human immunodeficiency virus (HIV) antibod y,hepatitis B surface 
antigen (HBsAg), or hepatitis C virus antibody (anti-HCV) ;
16. Participate din any interventional clinical trials within 30 days before screening or had 
participated in this current trial previously;
17. Are related to those persons involved directl y or indirect ly with the conduct of this study
(i.e., principal investigator, sub inve stigators , studycoordinators, other site personnel, 
emplo yees of Johnson & Johnson subsidiaries, contractors of Johnson & Johnson, and the 
families of each).

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
228.3. Subject Withdrawal Criteria
Subjects have the right to withdraw from the stu dy at any time for any reason without
compromising their rights to receive further treatment.  The investigator and/or the Sponsor
may terminate a subject from investigational product and/or study follow -up in the event of any
of the following:
Serious eligibility or on-studyviolation of the protocol
Medical reasons that are considered significant by the subject, investigator, or Sponsor
AEs
Intercurrent illness
Medical reason unrelated to the study
Non-medical reasons
oCompliance problems
oSubject withdrew consent
Pregnanc y
Treatment was unblinded
Administrative or other reasons
Should a subject decide to withdraw from the study afterbeginning Day 1Baseline procedures, 
he or she will be strongly encouraged to complete all end -of-studyassessments and the follow-
up telepho ne call.  I n case of questions surrounding the circumstances that a subject needs to be 
withdrawn from the study (e.g., protocol deviation), the Sponsor or its designated 
representative should be consulted.  The reason for withdrawal will be documented in the 
source document and CRF.
If a subject does not return for a scheduled visit or cannot be reached for the f ollow-up phone 
call, the staff will attempt to contact the subject at least three times by telephon e, and lastl y, by
certified letter.  The outcom e for each attempt will be recorded in the source document. The 
investigator should inquire about the reason for withdrawal and follo w-up with the subject 
regarding a nyunresolved AEs.
If the subject withdraws from the study and also withdraws consent for disclosure of future 
information, no further evaluations will be performed and no additional data will be collected.  
The Sponsor may retain and continue to use an y data collected before such withdrawal of 
consent.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
239. INVESTIGATIONAL PROD UCT MATERIALS AND 
MANAGEMENT
9.1. Investigational Product
Investigational products and placebo will be supplied by the Sponsor in bulk containers in an 
unblinded manner. In order to maintain the double- blind status of the study , the site must 
adhere to the following general storage, dispensing, and dosing procedure s.
The site will delegate a qualified third part y and back -up staff member(s) who will be 
responsible for dispensing and administering study medication and who will have no 
other direct or indirect role in the exec ution of this study .
The Sponsor will provide a randomization schedule directl y to the qualified third party 
individual . The r andomization schedule will be kept in a locked, secured area with 
access limited to only  the assigned third part y individual and u n-blinded monitor . 
Covered dosing cups willbe used by the assigned third part y dispenser to transport the 
assigned investigational product from the designated dispensing room to the subject’s 
room.
Detailed dosing procedures to ensure maintenance of the double -blind status of the study  are 
provided in Section 9.7 .
9.2. Description of Study Product
A description of the , acetaminophen, ibuprofen, and placebo investigational 
products are p rovided in Table 3. 
Table 3: Investigational Product
Product ACM 
(1000 mg)IBUb
(400 mg)Placebo
Dosag eForm Caplet Liqui d-filled Capsule Caplet
Rout e ofAdministration Oral Oral Oral
Unit Dose 500mg 200mg Notapplicable
Physical Description White caplet Tealliquid-filled
capsuleWhite caplet

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
24Table 3: Investigational Product
Product ACM 
(1000 mg)IBUb
(400 mg)Placebo
Manufacturer/Brand J&J Consumer 
Inc., McNeil
Consumer Health 
Division / TylenolPfize r/Advil          
Liqui -Gel®Catalent
b:Ibuprofen is solubilized asthefreeacid andpotassium salt.
9.3. Investigational Product Packaging and Labeling
 
9.4. Investigator Unblinding
If, in the opinion of the Investigato r, it is necessary to break the treatment code for safe ty 
reasons and circumstances allow, the Investigator will first contact the Designated Ph ysician 
Representative or designee for consultation about breaking the stu dy blind. If there is a 
medical emergency and the Investigator deems it necessary to know the subject’s study  
treatment urgent ly for the subject’s proper medical care, the Investigator may  break the 
treatment code immediatel y, and then contact the Designated Phy sician Representative or 
designee as soon as possible afterward.
In the event of a medical emergency  that necessitates breaking the code, the third- party
person(nel) will be permitted to inform the I nvestigator what study  drug the subject was given.
When the blind is broken, the I nvestigator will notify  the Sponsor within 24 hours after 
determining that it is necessary  to unbli nd the treatment assignment and document the reason 
and date of the unblinding. The event will also be recorded in the CRF and in the source 
document. Any AE or SAE associated with breaking the blind must be recorded and reported 
as specified in this pro tocol.
Once the treatme nt is unblinded, the subject must be discontinued from the study and followed 
until the event is resolved. The rationale, date, time, and attempts to contact the Sponsor must 
be documented in the source document. The studysite should take the necessary measures to 
maintain the treatment blind throughout the studyand prevent a ny unintended or premature 
unblindin g.
9.5. Method of Assigning Subjects to Treatment Groups
The randomization schedule will be generated b ythe Sponsor to ens ure treatment blinding. The 
site will keep the randomization schedule in a locked, secured area with access limited to only  

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
25the assigned third- partyperson(nel), back -up staff member, and  un- blinded monitor .After 
meeting the appropriate post -surger ycriteria, subjects will be randomized to receive one of 
four treatments (   ACM 1000 mg , IBU 400 mg or placebo ) in a 4:4:2:1 
ratio.  Subjects will be stratified by gender and baseline pain (moderate or severe). For subjects 
with moderate baseline pain, r andomization numbers will be assigned to subjects in sequential 
order starting with the lowest available number within the appropriate gender stratum. 
Similarl y for subjects with severe baseline pain intensit y, subjects will be assigned in 
sequen tial order starting with the highest available number in the appropriate gender stratum.
9.6. Study Product Storage, Accountability and Disposal
The investigator, or an approved representative, e.g., pharmacist, will ensure that all 
investigational product is stored in a secured area, atroom temperature, 68 ºF to 77 ºF (20ºC to 
25 ºC)and in accordance with applicable regulatory requirements.
The investigator must maintain adequate records documenting the receipt, use, loss, or other 
disposition of the investigational product on the Investigational Product Accountability Log 
supplied by the Sponsor.  The log must identify the investigational product and randomization 
number, and account for its disposition on a subject-by-subject basis, including specific dates
administered and quantities. The logmust besigned bythe individual who dispensed the 
investigational product, and copies must be provided to the Sponsor . All Investigational 
Product and Investigational Product L ogs are kept together in a secure, double -locked location 
with access onl y allowed to the third- party person(nel) , back -up staff member and un-blinded 
monitor . At the end of the study, the Sponsor will provide instructions regarding the disposition 
of an y unused and exhausted investigational product.  Thestudysite must maintain accurate 
and adequate records including shipment receipt and return of unused investigational product 
shipments.
9.7. Preparation, Dispensing and Administration of Investigational 
Product
Investigation alproduct prep aration and dispensing will be performed on Day  1, following 
dental surgery . For subjects who meet the randomization criteria, an independent third part y 
dispenser will administer one of the following study  treatments with up to 180 ml of water at 
ambient temperature to blindfolded subjects :

a single 1000 -mg dose of acetaminophen as two commercial ACM 500 mg caplets,
a single 400 -mg dose of ibuprofen as two commercial IBU 200 mg liquid -filled 
capsules, or
a single dose of two placebo caplets .

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
26Baseline pain assessments and drug administration will be completed in the subject’s room. 
The third- party dispenser will prepare study  medication for each subject in a designated 
dispensing room. Study medication will be dispensed at the time that the subject’s pain level is 
determined b y verbal assessment, just prior to the completion of the baseline categorical pain 
severit y scale and the baseline 11-point [0 -10] pain intensity  numerical rating sca le [PI -NRS] .
The study  coordinator will communicate the subject’s pain severity  and gender to the 
dispenser. The dispenser will assign the next available randomization number from the 
appropriate stratum. The dispense r will dispense the appropriate study  treatment from the 
appropriate bulk suppl y containers into an ind ividual dosing cup . The double -blind label with 
the same randomization number will be affixed to the dosing cup and the tear -off portion of the 
label will be attached to the patient ’s source documents. The third- partydispenser will 
complete the study  drug dispensing record .The study  drug dispensing record will remain in a 
secure and locked area, with access limited to the unblinded third- party dispenser ,back -up
staff member , and un- blinded monitor . A second individual, with no other study  involvement, 
will witness the prepa ration and dispensing process. No other study  personnel will be present in 
the designated dispensing room at the time of study  drug dispensing.  The dispenser will ensure 
the dosing cup containing the randomized study  treatment is covered prior to exiting the 
dispensing room. 
The third- partydispenser will inform the blinded study  coordinator once the study  drug is 
dispensed and is read y to b e administered to the subject. Following completion of the baseline 
categorical pain severity  scale and baseline pain intensity  numerical rating scale , the study  
coordinator will blindfold the subject and then exit the subject’s room to inform the dispenser 
that the pain assessments are completed and confirm that the pain severit y has not changed 
from the verbal assessment used to determine the appropriate randomization, and that the pain 
intensity  numerical rating scale score qualifies the subject for randomization. If the baseline 
categorical pain severity  has changed, new study  drug from the corresponding pain stratum will 
be prepared. The dispenser will deliver the study  drug from the designated dispensing room to 
the subject’s room in a covered dosing cup to ensure no other individua l will be able to see the 
study  drug in the bottle .No other study  personnel, other than the third- party witness, will be 
present in the subject’s room at the time of dosing.
After the entering the blindfolded subjec t’s room and while the subject is sittin g up, the 
dispenser willhand the dosing cup containing the study  treatment to the blindfolded subject
and instruct the subject to empty  thecontents of the dosing cup directl y into their mouth and 
then swallow the study  medication immediately with up to 180 ml of water at ambient 
temperature . The dispenser will inspect the subject’s oral cavit y to ensure that the study  
treatment was swallowed .The time at which the subject swallows thestudy  medication will be 
recorded as Time 0. Study  drug will be adminis tered to the subject within 5 minutes of the 
completion of the baseline pain assessments.
If a subject vomits after dosing, the subject will not be r e-dosed but will remain in the stud y.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
279.8. Product Quality Complaints
A Product Quality Complaint (PQC) is any written, electroni c, or oral communication, quer y, 
observation, or issue rela ted to the identit y, quality, durabilit y, reliability , safe ty, efficacy or 
performance of investigational supplies.  Any PQC discovered during the initial invento ry 
should fol low the instructions provided on the receipt letter; no PQC form should be filed for 
issues identified when opening or unpacking a shipment. Subsequentl y,anyobservation of a 
PQC requires immediate notification to the Sponsor’s Clinical Supply  Manager via a 
completed PQC form and telephone call.  The PI or designee should also complete, sign, and
forward acopyof the PQC form to the Clinical Supply  Manager .
In addition, PQC information must be included on the I nvestigational Product Dispensing and 
Accoun tability Log or equivalent in the comments field and completed b y the third- party
dispenser .  The Clinical Supply  Manager listed can assist you or answer questions related to 
this process. To aid in the initial conversation and understanding of a PQC, the site staff may
be asked to photograph the issue and send it to the Clinical S upply Manager .

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
2810. STUDY PROCEDURES
10.1. Overview
Collection of adverse events and concomitant medications will start after the study-specific 
informed consent document has been signed and continue until completion of the follo w-up 
procedures.  The Schedule of Activities (Table 1) summarizes dose administration and the 
timing and frequency of safe tyandefficac yprocedures and measurements. In the event of 
abnormal safety findings during the conduct of the study , the attending p hysicia nmay request 
additional safe tyevaluations, either immediately or subsequently atafrequency  considered 
appropriate.
10.2. Screening Visit
Informed consent should be obta ined from the subjects before a nystudy related assessments 
are conducted.
 Inclusion and exclusion criteria
 Demograp hy
 Significant medical history –the condition, diagnosis, or surgical procedure
 History of medication and other treatments (within 30 day s)
 Vital signs:  resting blood pressure, heart rate, respiratory rate, oral temperature
 Height, weight and bo dymass index (BMI) assessment
 A serum sample will be collected to test for HIV antibod y, hepatitis B surface antigen
            (HBsAg) and hepatitis C virus antibody (anti-HCV)
 Urine drug screen test , incl uding a test for buprenorphine
 Urine pregnancy test on females with childbearing potential
Subjects who meet all inclusion/exclusion criteria will be scheduled for the dental procedure 
within 30 day s after Screening.
10.3. Baseline Visit (Day of Surg ery)
The following will be re-evaluated prior to the surgical procedur e, and the evaluations will be 
recorded in the source documen ts and the CRF. For data collected on both Screening and 

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
29Baseline Visits with the exception of age , only the data collected at B aseline will be recorded 
on the CRF.
 Inclusion and exclusion criteria
 Anychanges to medical and surgical history
      Collection of age
 Any changes to prior and concomitant therapies
 Vital signs: resting blood pressure, heart rate, respiratory rate, oraltemperature
 Urine drug scr een test, including a test for buprenorphine
 Urine pregnancy test on females with childbearing potential
A negative urine drug screen and urine pregnancy test (for women of childbearing potential)
must be obtained on the same day as the surgical procedur e.
10.3.1. Randomization
After the dental procedure, subjects will be asked to rest quietly at the stud y center until they  
experience both post -surgical pain of at least moderate pain on a categorical scale ranging from 
(0) none to (3) severe and at least a score of 5 on the 11- point (0-10) PI- NRS within 4.5 hours 
of the last stitch during oral surger y.  Subjects who did not me et these criteria will be 
considered a screen failure.
Randomization numbers will be assigned to subjects in sequential order starti ng with the lowest 
available number within the appropriate gender stratum for subjects with moderate baseline 
pain and starting with the highest available number in the appropriate gender stratum for 
subjects with severe baseline pain intensity .  Randomize d subjects will receive their dose of 
investigational product, which will be considered time 0.  The administration of investigational 
product should occur as described in Section 9.7. Site staff will ins pect the subject’s oral 
cavity to ensure that the investigational product was swallowed.
10.3. 2. Postdose Assessments
Two stopwatches labeled asperceptible and as meaningful will be used to measure “perceptible 
pain relief” and “meaningful pain relief”, r espective ly.  The face of each stopwatch will be 
covered to prevent the subject from seeing the running clock. Subjects willonly be given the 
second stopwatch after they stop th e first one.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
30Sitepersonnel will instruct thesubject: “I would like you to stop the first stopwatch 
(perceptible ) when you first begin to feel an ypain relieving effect whatsoever of the drug, that 
is, when you first feel any pain relief.  This does not necessaril y mean you feel completely
better, although you might, but when youfirstfeelany difference in the pain you have now.  
As soon as y ou stop the stopwatch please press y our call light to notify thestudycoordinator.  I 
would like y ou to stop the second stopwatch ( meaningful ) when you have meaningful pain 
relief, that is , when the relief from the starting pain is meaningful to you. As soon as you stop 
the stopwatch, please press yo ur call light to notify thestudy coordinator.” Upon dosing, the 
investigator or the designated site staff will start both stopwatches at the same time.  Once the 
stopwatch has been stopped, the investigator or designated stu dy staff will retrieve the 
stopwatch and record the time in the source documents and CRF.
Pain relief and pain intensity will be assessed using the NRS (see APPE NDIX1)at 0.25, 0.5,
0.75, 1, 1.25, 1.5, 2, 3, and 4hours (± 5 minutes) after the dos e, at the time of rescue (if 
applicable), and at the time of meaningful relief (if applicable ).
At the end of the 4-hour assessment, at the time of rescue, or at the time of earl y termination if 
a subject is discontinued or withdrawn earlier than four hours after dosing, subjects will be 
asked to report their overall impression of thera py (Subject Global Evaluation) as (0) Poor, (1) 
Fair, (2) Good, (3 ) Very good, or (4) Excellent. Subjects who use rescue thera py will continue
in the study and assess pain and relief through four hours .
10.3. 3. End of Study
End of s tudyis defined as completion of the 4-hour assessments or at the time of ear ly 
terminatio n if a subject is discontinued or withdrawn earlier than four hours after the dose. 
Subjects who rescue are to remain at the stu dy site through the 4- hour assessments, which is 
their time of end of stu dy.
10.4. Follow-Up Phone call
Subjects will be intervie wed bytelephone to follow up on appropriate postsurgical medical 
care and changes in their health, including a ny emergent or existing AEs.  The interview will 
occur between the 5th-7thdayafter the dental surger yunless the 5thday occurs on a Friday  in 
which case the interview period can be extended to the next business day . Three attempts should 
be made to contact the subject by phone. If the subject cannot be contacted by  phone b y the 7th
day after the dental surgery or the next business day  if the 5thday after dental surgery  occurs on 
a Friday, th en a certified letter should be mailed to the subject on the 7thday after the dental 
surgery or the next business day  if the 5thday after surgery  occurs on a Friday . Ever yeffort 
will be made b ythe inve stigator or designated study staff to adhere to the schedule. Additional 
postsurgical medicines (e.g., antibiotics or analgesic prescriptions) or therapies (e.g., ice packs) 
that are taken after the 4-hour and S ubject Global assessments will be recorded on the subject’s 
source documents, but not in the CR F; however concomitant medications taken for an adverse 
event will be recorded on the CRF.  E mergent or existing AEs will be recorded in both the 
source documents and CRF.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
3110.5. Life Style Guidelines
10.5.1 . Meals and Dietary Restrictions
Onlyclear, non- caffeinated liquids may be consumed from the time of surgery until two hours 
following administration of the investigational product.  After two hours, subjects may  
consume soft foods consistent with having dental surgery.
10.5.2. Alcohol, Caffeine and Tobacco Consumption / Restrictions
Use of alcoholic beverages within three days before the oral surgical procedure and during the
study is prohibited.  In addition, subjects must refrain from the use of an y methylxanthin e-
containing products (e.g., chocolate bars or beverages, coffee, tea, colas, or caffeinated energy
drinks) and tobacco or nicotine containing products (e.g., cigarettes, cigars, nicotine 
replacement therapies) within 12 hours before surgery and during the study while confine d at 
the site.
10.5.3. Physical Activity Requirements / Restrictions
Walking at a normal pace will be permitted.  Subjects will remain sitting upright or semi -
reclining for dosing and at least 4 hours immediately following tr eatment administration, 
except for short durations to use the restroom.
10.5.4. Contraception for Females
Female subjects are considered not of childbearing potential if they  meet at least one of the 
following criteria:
Had a h ysterectom y and/or bilateral oophorectomy
Had sterilization surgery
Are post -menopausal (i.e., amenorrheic for at least 12 months prior to the Baseline 
visit)
Females with childbearing potential who are sexually active must agree to continue using a 
medically acceptable form of birth control during the study and for 30 day s after taking the 
investigational product.  
Medically  acceptable methods of birth control for this study include:
a.Established use of hormonal methods of contraception (oral, injected, implanted, patch 
or vaginal ring)
b. Barrier methods of contraception with spermicide: condom or occlusive cap 
(diaphragm or cervical/vault caps) with spermicidal foam, gel, film, cream, or 
suppository .

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
32c.Intrauterine device (IUD) or intrauterine s ystem (IUS)
d.Surgical sterilizati on (e.g., vasectom y that has been confirmed effective b y sperm count 
check, tubal occlusion, hysterectom y, bilateral salpingectomy)
e.Abstinence from heterosexual intercourse: When this is in line with the preferred and 
usual lifesty le of the subject.  Pe riodic abstinence (e.g., calendar, ovulation, 
symptothermal, post- ovulation methods) and withdrawal are not acceptable methods of 
contraception. 
Sexuall y active female subjects who use hormonal contraception must have used a stable dose 
for 30 da ys before surger y.  If hormonal contraception has been used for less than 30 days or if 
the dose has changed within the past 30 days, subjects must agree to also use a barrier method 
during the stud yandupto30 day s after taking the investigational product.
10.5. 5. Contraception for Males
If amale subject is sexually active with a woman of childbearing potential and has not had a 
vasecto my with confirmation of azoospermia, he must either agree to use a condom with 
spermicidal foam/gel/film/cream during thestudy or must confirm that his female partner has 
used a medically acceptable form of birth control for at least 30days before study  drug 
administration and will continue to do so during the study .  Medicall y acceptable forms of birth 
control for a male subject ’s female partner of childbearing potential include prescription oral, 
vaginal or transdermal contraceptives, contraceptive implants or injections, intrauterine device, 
diaphragm or cervical cap, with spermicide . 
10.6. Prior and Concomitant Medications an d Therapies
Medications that are taken from 30days prior to surger yuntil study end(asdefined in Section 
10.3. 3)will be recorded in the source documents and CR F.  Medications taken between study
end and the follo w-up interview (except for those taken for an adverse event) will be recorded 
in the source documents, but not in the CR F. Medications taken between study  end and the 
follow -up interview for an adverse event will be recorded in the source documents and CRF .
10.6.1. Permitted Th erapies
Female subjects taking hormonal contraceptives will be instructed to continue before, during, 
and after the study as per protocol.  All subjects will be permitted a short -acting local 
anesthetic, lidocaine with or without epineph rine, and/or nitrous oxide during dental surger y. 
Topical benzocaine is also allowed .
10.6.2. Prohibited Therapies
Long-acting anesthetics are prohibited during the dental surgery. Other medications prohibited 
before entry intothestudy are listed under Exclusion Criteria.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
33The use of any oral OTC or prescription (except contraceptive medications and those required 
for use during oral surgical procedure such as short- acting local anesthetics), vitamin, or herbal 
supplements are prohibited within 5 da ys or 5 hal f-lives (whichever is longer) before the oral 
surgical procedure and during the stu dy.
10.7. Rescue Medicine
Subjects will be encouraged, but not required, to wait at least 1 hour after investigational 
product dosing before using the rescue medicine, hydrocodone bitartrate 7.5 mg / ibuprofen 
200mg tablets , if the severity of the subject’s pain increases to an intolerable level.
Hydrocodone bitartrate 7.5mg / ibuprofen 200 mg tablets will be used according to its 
product labelin g.  Use of rescue medic inewillbe recorded in the source document and CRF.  
Once rescue medicine has been administered, the stopwatch(s) will be collected from the 
subject.  No stopwatch data will be recorded after use of rescue medication; howeve r, subjects 
will conti nue to re cord pain intensity and pain relie f.

, 
Protocol:CO- 170317095828 -PACT
FINAL 16May2017
3411. ASSESSMENTS
11.1. Efficacy Assessments
The investigator or designated st udystaff will ensure the subjects complete the pain intensity  
and pain relief assessments at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, and 4hours (± 5 minutes) after 
dosing.  Subjects will record their pain intensity and pain relief directly onto the respective 
source worksheet.  Evaluations will in clude the following parameters:
Pain intensity
oFour-point categorical scale collected at baseline: (0)no pain; (1) mild pain; (2) 
moderate pain; (3) severe pain
o0-10 PI-NRS collected at baseline and at each time point (including at time of 
rescue and at time of meaningful relief)
Pain relief – 0-10 PR-NRS collected at each time point (including at time of rescue and 
at time of meaningful relief)
Time to perceptible pain relief – recorded using stopwatch perceptible
Time to confirmed perceptible pain relief is defined as the time to perceptible pain 
relief, provided that the subject subsequently stopped the second stopwatch indicating 
meaningful pain relief.
Time to meaningful pain relief – recorded using stopwatch meaningful
Time to rescue –time when rescue therapy was administered
Subject global evaluation –subject’s overall impression of the investigational product 
at hour 4, at time of rescue , or at the time of earl y termination if a subject is 
discontinued or withdrawn earlier than four hours after dosing:
(0) poor (1) fair (2) good (3) very good (4) excellent
11.2. Safety Assessments
Safety will be monitored via AE reporting.  If an AE is reported , the subject will be asked to 
elaborate on the nature of the event.  The investigator or designated stu dy staff will evaluate 
and record according to the Adve rse Event Reporting section of the protocol.

 
Protocol:CO- 170317095828 -PACT
FINAL 16May2017
35Normal consequences of dental surgery (e.g., dry-socket, pain, swelling, bruising) are not 
considered AEs unless the investigator believes the condition worsened or was aggravated 
following stu dy drug therap y.
11.3. Vital Signs
Vital signs will be collected at screening and baseline.  All vital signs (blood pressure, pulse, 
respiratory rate, and oral body temperature) will be collected after at least 5 minutes of rest in a 
supine or semi - reclining position in a quiet setting without distractions (e.g., television, cell 
phones). Systolic and diastolic blood pressure and pulse rate measurements will be assessed 
with a completel yautomated device, consisting of an inflatable cuff and an oscillatory
detection system.  All values will be re gistered on an automated recorder so that measurements 
are observer indepe ndent. Manual techniques will be used onl yif an automated device has 
malfunctioned.  Respiratory rate will be measured over at least 30 seconds. Oral bo dy 
temperature will be mea sured using a Sponsor -approved standard method. Abnormal vital 
signs collect ed at screening and baseline will be assessed by  the medicall y qualified 
investigator to confirm that the subject is medically suitable for study  participation.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
3612. ADVERSE EVENT REPORTING
12.1. Introduction
All observed or volunteered AEs regardless of tr eatment grou p,device group or suspected 
causa l relationship to the investigational product(s) will be reported as described in the 
following sections.  For all AEs, theInvestigator or medical ly qualified individual 
(MD/DO/Dentist) must pursue and obtain information adequate both to determine the outcome 
of the AEand to assess whether it meets the criteria for classification as a Serious Adverse 
Event (SAE) requiring immediate notification (within 24 hours) to the Sponsor or its 
designated representative.  For all AEs, sufficient information should be obtained by the 
Investigator or medically qualified individual (MD/DO/Dentist) totryto determine causalit y.
TheInvestigator / siteis required to assess causalit y.  For AEs with a suspected causal 
relationship to the investigational product, follow-up by theInvestigator or medically  qualified 
individual (MD/DO/Dentist) is required until the event or its sequelae r esolve or stabilize at a 
level acceptable to the Investigator, and the Sponsor concurs with that assessment.
12.2. Reporting Period
All AEs, whether serious or non -serious will be recorded on the CRF in the AE section 
beginning from the time the informed consent is signed and dated. Informed consent is 
considered the point at which the subject is p articipating in the clinical study and all events are 
captured even if it is prior to undergoing a ny study-related procedure and/or receiving 
investigational product or investigational devic e. Non-serious - AEs will be reported through 
the subject’s last study visit (or termination if the subject terminates early from thestudy for 
anyreason).  Serious AEs will be reported through and including 30 calendar days after 
administration of the subject’s last dose or exposure to investigational product.  Serious AEs 
require immediate notification to the Sponsor or its designated representative.  Any SAE 
occurring a ny time after the reporting period must be promptly reported if a causal relationship 
to studyproduct is suspected.
12.3. Definition of an Adverse Eve nt
An AE is an y untoward medical occurrence in a clinical investigation whether or not a subject 
is administered the investigational product ormedical devic e.  The event does not need to have 
a suspected causal relationship with the investigational produ ct or devic e.  An AE can therefore 
be any unfavorable and unintended sign, sy mptom, disease, orinjury  temporally associated 
with the use of an investigational product or device, whether or not related to the 
investigational product or devic e.  Examples of -AEs include but are not limited to:
Abnormal test findings,

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
37Clinically important symptoms and signs,
Changes in p hysical examination findings ,
Hypersensitivit y, and
Progression/worsening of under lying disease.
Additionall y,theymayinclude the signs or symptoms resulting from:
Investigational product overdose,
Investigational product withdrawal,
Investigational product abuse,
Investigational product misuse,
Investigational product interactions,
Medication errors,
Investigational product dependency
Exposure in utero, and
Study  related procedure
12.4           Abnormal Test Findings
The criteria for determining whether an abnormal objective test finding should be reported as 
an AEs are as follows:
Test result is associated with accompa nying symptoms, and/or
Test result requires additional diagnostic testing or medical/surgical intervention, 
and/or
Test result leads to a discontinuation from the study, significant additional concomitant 
treatment, or other thera py,and/or
Test result is considered to be an AE bytheInvestigator or the Sponsor

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
38Mere ly repeating an abnormal test, in the absence of any of the above conditions, does not 
constitute an AE.  A ny abnormal test result that is determined to be an error does not require 
reporting as an AE.
12.5. Serious Advers e Events (SAE)
An AE or suspected adverse reaction is considered “serious” for a drug study if, in the view of 
either the Investigator (ph ysician/dentist) or the Sponsor, it r esults in any  of the following 
outcomes:
Results in death,
Is life-threate ning (immediate risk of death),
Requires inpatient hospitalization or prolongation of existing hospitalization,
Results in persistent or significant incapacity orsubstantial disruption of the abilit yto 
conduct nor mal life functions,
Results in congenital anomal y/birth defect,
Is considered medically s ignificant (medical and scientific judgment should be 
exercised in deciding whether expedited reporting is appropriate in ot her situations, 
such as important medic al events that may not result in death, be life-threatening or
require hospitalization but may be considered a serious adverse drug experience when, 
based upon appropriate medical judgment, they may jeopardize the subj ect andmay
require medical or surgica l intervention to prevent one of the other outcomes listed 
above).  Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an Emergency  Room or at home, blood d yscrasia, or convulsions 
that do not result in hospitalization; or development of drug dependency  ordrug abuse, 
or malignanc y), or,
Is a suspected transmission of an y infectious agent via a medical product ( medically 
significant) and should be reported as an SAE in the category  ‘Other medically  
important cond itions’.
12.6           Hospitalization
Adverse events reported from clinical studies associated with hospitalization or prolonging 
hospitalization are considered serious.  Any initial admission (even if less than 24 hours) to a 
healthcare facility meets these criteria.  Admission also includes transfer within the hospital to 
an acute/intensive care unit (e.g., from the p sychiatric wing to a medical floor, medical floor to 
acoronary care unit, neurological floor to a tuberculosis unit).  Hospitalization does n ot include 
the following:
Rehabilitation facilities,

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
39Hospice facilities,
Respite care (e.g., caregiver relief),
Skilled nursing facilities,
Nursing homes,
Emergency room visits (unless the reason for the emergency room visit meets one of 
the other outcomes in the definition of serious), and/or
Same daysurgeries (as outpatient/same da y/ambulator y procedures) 
Hospitalization or prolongation of hospitalization in the absen ce of a precipitating, clinical 
AE is not in itself aSAE.  Examples include:
Admission for treat ment of a pr e-existing condition not associated with the 
development of a new AE or with a worsening of the pr e-existing condition (e.g., for
work -up of persistent pr e-treatment lab abnormality ),
Social admission (e.g., subject has no place to sleep),
Administrative admission (e.g., for yearly phy sical exam),
Protocol -specified admission during a clinical study (e.g., for a procedure required by
thestudy protocol),
Optional admission not associated with a precipitating clinical AE (e.g., or electiv e 
cosmetic surgery ),
Pre-planned treatments or surgical procedures should be noted in the baseline documentation 
for the entire protocol and/or for the individual subject.
Diagnostic and therapeutic non -invasive and invasive procedures, such as surger y, 
should not be reported as AEs.  However, the medical condition for which the 
procedure was performed should be reported if it meets the definition of an AE. For 
example, an acute appendicitis that begins during the AE reporting period should be 
reported as the AE and the resulting appendectom y should be recorded as treatment of 
theAE.
12.7. Resolution
The Investigator will be required to assess the outcome of the AE for investigational product
(drug or device) as one of the following:
Resolved,

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
40Not Resolved,
Fatal,
Resolved with sequelae,
Resolving, or
Unknown
Anycausal ly-related AEs unresolved upon completion of the last study visit willbefollowed 
up by thestudystaff until the event or its sequelae resolve or stabilize at a level acceptable to 
theInvestigator and recorded on the CRF.  An event that is assessed as resolved with sequelae 
or resolving indicates that the subject has stabilized to a level acc eptable to the Investigator and 
has concurrence bytheSponsor.
12.8. Severity Assessment
The severi ty of AEs will be assessed bytheInvestigator or medicall yqualified individual 
(MD/DO/Dentist) using the following general categori cal descriptors:
MILD:Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with subject's usual function or normal everydayactivities
MODERATE: Sufficient discomfort is present to cause interference to some ext ent with 
subject's usual function or normal every dayactivity
SEVERE: Extreme distress, ca using significant impairment of functioning or 
incapacitation; interferes significantl y with subject's usual function; prevents normal everyday
activities
Note the distinction between the severi ty and the seriousness of an AE.  A severe event is not 
neces sarily a serious event.  For example, a headache may be severe (interferes significantl y 
with subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
12.9. Causality Assessment
The Investig ator’s ormedicall yqualified individual (MD/DO/Dentist) assessment of causalit y
for investigational product (i.e., relationship to investigational product) must be provided for 
all AEs (serious and nonserious).  An Investigator’s causality assessment is t he determination 
of whether there exists a reasonable possibility that the investigational product caused or 
contributed to an AE.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
41Not Related -An AE that isnot related to the use of the drug
Doubtful - An AE for which an alternative explanation is m ore likel y, e.g., concomitant 
drug(s), concomitant disease(s), or the relationship in time suggests that a causal 
relationship to investigational product is unlikely.
Possible - An AE that might be due to the use of the drug.  An alternative explanation,
e.g., concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in 
time is reasonable; therefore, the causal relationship to investigational product cannot 
be excluded.
Probable - An AE that might be due to the use of the drug. The relationship in time is 
suggestive (e.g., confirmed by dechallenge ) and an alternative explanation is less likely, 
e.g., concomitant drug(s), concomitant disease(s).
Very Likely -An AE that is listed as a possible adverse reaction and cannot be 
reasonab lyexplained by an alternative explanation, e.g., concomitant drug(s), 
concomitant disease(s). The relationship in time is very suggestive (e.g., it is confirmed 
by dechallenge and rechallenge) for a causal relationship to the drug.
If the Investigator de termines a SAE is associated with study procedures, the Investigator must 
record this suspected causal relationship in the source documents and CRF, as appropriate, and 
report such an assessment in accordance with the SAE reporting requirements, if applica ble.
12.10. Exposure In Utero
For investigational products within clinical studies and for marketed products, an exposure in 
utero (EI U)occurs if:
1.   a woman is exposed to the investigational product at an y time between her last menses 
prior to concepti on through the delivery ofthebaby.
2.   There isapossibility of intrauterine exposure to drug via semen from the male partner who 
is taking the investigational product at the time of conception, thereb ypossibly  exposing the 
fetus to the product.
If any study subject or study subject’s partner becomes or is found to be pregnant during the 
studysubject’s participation, the Investigator must report the pregn ancyto the Sponsor on a 
Pregnancy Notification Form (to be provided by the Sponsor when applicabl e). In addition, the
Investigator must submit information regarding environmental exposure to a Sponsor product 
in a pregnant woman (e.g., a nurse reports that she is pregnant and has been exposed to a
cytotoxic product by  inhalation or spillage) using the Pregnanc yNotification Form.  This must 
be done irrespective of whether an AE has occurred and notification must occur within 24 
hours of awareness of the pregnanc y. Initial notification via telephone to the Sponsor’s study
team contact must occur immed iately upon theInvestigator site’s awareness of the pregnanc y. 
The Pregnanc y Notification Form must then be sent to the Sponsor within 24 hours of the site’s 

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
42awareness. The information submitted should include the anticipated date of delivery (see 
below for information related to induced termination of pregnancy ).
Follow-up is conducted to obtain pregnancy outcome information on all EIU reports.  The 
Investigator will follow the pregnancy until completion or until pregnancy termination (i.e., 
induced abor tion) and then notify the Sponsor of the outcome.  The Investigator will provide 
this information as a follow- up to the initial Drug Exposure during Pregnancy  Collection Form 
A and/or End of Pregnancy Collection Form B (provided by the Sponsor when applica ble).  
The reason(s) for an induced abortion should be specified.  An EIU report is not created when 
an ectopic pregnancy report is received since this pregnancy is not usuall yviable.  Rather, a
SAE case is created with the event of ectopic pregnancy.
TheInvestigator should follow the procedures for reporting SAEs if the outcome of the 
pregnancy meets the criteria for immediate classification as a SAE (i.e., spontaneous abortion, 
stillbirth, neonatal death, or congenital anomal y[including that in an abor ted fetus, stillbirth, or 
neonatal death]). I n the case of a live birth, the “normalit y” of the newborn can be assessed at 
the time of birth (i.e., no minimum follow -up period of a presumably normal infant is required 
before an End of Pregnancy Collection Form B can be completed).  The “normalit y” of an 
aborted fetus can be assessed by gross visual inspection, unless pre- abortion test findings are 
suggestive of a congenital anomaly.
Additional pregnancy outcomes that are classified as SAEs and should be reported as such
include:
“Spontaneous abortion” includes miscarriage and missed abortion.
All neonatal deaths that occur within 1 month of birth, without regard to causalit y.
Anyinfant death after 1 month that the Investigator assesses as possib ly related to in 
utero exposure to the investigational product.
12.10.1. Withdrawal Due to Adverse Events
When a subject withdraws due to a SAE, the SAEs must be reported in accordance with the 
report ing requirements defined below.
12.10.2. Eliciting Adverse E vent Information
The Investigator is to report all directly observed AEs and all AEs spontaneousl yreported by 
thestudy subject. In addition, each study subject will be questioned abo ut AEs.
12.10.3. Reporting Requirements
Each AE is to be assessed to de termine if it meets the criteria for a SAE. If aSAE occurs, 
expedited reporting will follow local and international regulations, as appropriate.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
43All AEs will be reported on the AE page(s) of the CRF.  A Clinical Serious Adverse Event 
(SAE) Report Form must also be completed if the event is considered to be serious. It should 
be noted that this Clinical SAE Report Form for collection of SAE information is not the same 
as the AE CRF.  Where the same data are collected, the forms must be completed in a 
consistent manner.  For example, the same AE term should be used on both forms.  Adverse 
events should be reported using concise medical terminology on the CRFs as well as on the 
form for collection of SAE information.
12.10.3.1.  Serious Adverse Event Reporting Requirements
If aSAE occurs, the Sponsor is to be initially notified bytelephone immediatel y upon 
awareness of the event by the Investigator’s site. Within 24 hours of the Investigator site’s
awareness of the event, the study site must send the Sponsor the Clinical SAE Report Form. 
This timeframe also applies to additional new information (follo w-up) on previously  forwarded 
SAE reports as well as to the initial and follow- up reporting of EIU cases. Inthe rare event 
that the I nvestigator’s site does not become aware of the occurrence of a SAE immediately
(e.g., if an outpatient study subject initially seeks treatment elsewhere), the I nvestigator’s site is 
to report the event immediately after learning of it as described and document the time of the 
studysite’s first awareness of the adverse event.
For all SAEs, the Investigator is obligated to pursue and provide information to the Sponsor in 
accordance with the timeframes for reporting specified above. In addition, an Investigator may
berequested bythe Sponsor to obtain specific addition al follow -up information in an expedited 
fashion.  This information may be more detailed than that captured on the adverse event CRF. 
In general, this will include a description of the A E in sufficient detail to all ow for a complete 
medical assessment of the case and independent determination of possible causality. 
Information on other possible causes of the event, such as concomitant medications and 
illnesses must be provided. In the case of a subject death, a sum mary of available autop sy 
findings (if available) and death certificate should be collected if permission is obtained from 
the subject’s fami ly.  For a hospitalization, a copyof the hospital discharge summary should be 
requested. If obtained, these docum ents (with subject’s personal identifiers redacted) should 
be submitted as soon as possible to the Sponsor or its designated representative.
Appropriate SAE forms will be provided to the study site at the initiation of the study.  Upon 
notification of an S AE at the study site, the Investigator or designated stud y site staff should 
call and speak to their Sponsor’s study manager contact immediately toinitiall ynotify them of 
theSAE.
Within 24 hours of awareness of the event, the Investigator or designated study site staff:
complete the Clinical SAE Report Form ([provided by the Sponsor] with as much 
information as possible, however at a minimum, the subject identification number, 
name of product, SAE, and name of reporter are required);
ensures the Inve stigator signs the Clinical SAE Report Form prior to sending to the
Sponsor;

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
44scans and emails (via secure email) the Clinical SAE Report Form to the Sponsor 
contacts.
The Sponsor contact information is maintained in the table below :
Table 4: Sponsor Contact Information
  
All nonserious adverse events are to be reported on the adverse event CRFs and wi ll be 
submitted to the Sponsor.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
4513. STATISTICS
The Sponsor will be responsible for the statistical ana lysis o fstudydata.  Detailed 
methodology for the statistical analy sis of the data will be documented in a Statistical Anal ysis 
Plan finalized and approved prior to database lock and release of randomization codes.
13.1. Samp le Size Determination
A simulation [3]was conducted based on the two previ ous dental pain studies 
 to evaluate the sample size and power 
within different effect size range s.  Based on the simulation results, the time to confirmed 
perceptible pain relief (TCPR) is identified as the p rimary  efficacy  endpoint, and the primary  
interest is to compare the median survival times in TCPR between  and ACM. Based 
on the assumption that the median survival time of  will be faster than that of ACM 
within the range of 5.0 –5.5 min utes, a sample size of n=240 for the  and ACM 
groups will provide 90% power. If the median survival time in TCPR of  is assumed 
tobe faster than that of IBU within the range of 6.0 – 6.5 minutes, the sample size of n=240 for 
the  group and n=120 for the IBU group will provide greater than 90%  power.
Based on the above, it is recommended that the eligible subjects will be randomly  assigned in a 
ratio of 4:4:2:1 , with 240, 240 , 120 , and 60 subjects being assigned to , ACM, I BU 
and placebo for a total of 660 subjects.
13.2. Analysis Sets
13.2.1. Efficacy Analysis Sets
The primary analysis set for the efficac yanalyses will include all subjects who are randomized .  
The per protocol set will exclude subjects who took rescue medi cation within 60 minutes after 
dosing, vomited within 60 minutes after dosing, and those with major protocol deviations.  The 
final pe r-protocol set will b e determined before unblinding.
13.2. 2. Safety Analysis Population
TheSafety Set will include all su bjects who are randomized and take investigational product.
13.2. 3. Subject Disposition and Protocol Violations
Subject disposition will be summarized by treatment group.  The number of subjects with 
protocol violations will be summarized in a table by treatment and violation as well as in a 
listing by subject.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
4613.3. Baseline and Demographics
Baseline and demographic characteristics will be presented by treatment group for each 
analysisset.  For continuous variables, descriptive summaries will include numb er of subjects, 
mean, standard deviation, median and range (min, max).  For categorical variables, the number 
and percent of subjects in each response category will be presented .
13.4. Previous and Concomitant Medica tions
Previous and concomitant medications will be coded.  Previous medications will be those that 
were discontinued before the surgery day.  Concomitant medications will be those continued 
through, or started on, the surgery day. In addition, those medications taken between study end 
and the follow -up interview for an adverse event will be considered concomitant medications .  
Medications taken after EndofStudy (see Section 10.3. 3)and up to the follo w-up call that 
were not taken for an adverse event will no t be collected on the CRF or summarize d. Previous 
medications and concomitant medications will be summarized by treatment in separate tables.  
Number and percentage of subjects receiving each coded medication will be presented by
treatment. Additionall y, concomitant medications taken by greater than or equal to 5% of 
subjects in at least one treatment g roup will be presented.
13.5. Efficacy Analysis
Primary efficacy endpoint
 Time to confirmed perceptible pain relief
Secondary efficacy endpoints
Time to m eaningful pain relief ;
Percentage of subjects with confirmed perceptible relief from 30 minutes to 
successivel y earlier minutes in one -minute increments (  versus placebo )
Tertiary efficacy endpoints
Percentage of subjects with meaningful pain relie f at 35, 40, and 45 minutes (  
 versus ACM) ;
Percentage of subjects with confirmed perceptible relief at 15, 20, and 25 minutes ;
Time weighted sum of pain intensity  difference from 0 to 4 hours (SPI D 0-4);
Time weighted sum of pain relief from 0 to 4 hours (TOTPAR 0 -4);
Pain relief (PAR) and pain intensity  difference (PID) scores at individual time points;
Time to rescue analgesic (duration of relief after dosing);

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
47Subject Global Evaluation.
13.6. Statistical Hypothes es and Treatment Comparisons
The p rimary  hypothesis is 
2 1 0 : M M H     vs   2 1 : M M HA 
where 1Mand 2Mare the median survival times of  and ACM in TCPR, 
respectivel y.
Besides the primary  hypothesis, the median survival times in TCPR between  and 
IBU will be compared. The median survival times in TMPR will be compared between  
vsACM and between  vs IBU.
The survival functions of the active treatments will be compared with the survival function of 
placebo.
To control the famil y-wise T ype I error rate at 0.05 for primary  and secondary  endpoints, the 
fixed sequence testing with fallback method will be used [4]. Table 5presents the order of the 
tests and the assigned α values for each ordered test. The comparison of  to I BU in 
TMPR is not included in the fixed testing sequence. Testing will commence with an assigned 
alpha = 0.049 and an alpha value of 0.001 will be reserved for the comparison of  
and placebo on the percentage of subjects with confirmed perceptible relief from 30 minutes to 
successivel y earlier minutes in one -minute increments.
Table 5: Order of Tests and Assigned Alpha Values
Pre-Assigned 
α-valueα-va lue available 
if previous test 
positiveα-value available if 
previous test(s) 
negative
TCPR  vs PLACEBO 0.049 --- ---
TMPR  vs PLACEBO None 0.049 None
TCPR  vs ACM None 0.049 None
TCPR  vs IBU None 0.049 None
TMPR  vs ACM None 0.049 None

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
48Table 5: Order of Tests and Assigned Alpha Values
Pre-Assigned 
α-valueα-va lue available 
if previous test 
positiveα-value available if 
previous test(s) 
negative
Percentage of subjects with 
confirmed perceptible relief from 
30 minutes to successively earlier 
minutes in one -minute increments 
 vs PLACEBO )0.001 0.05 0.001
13.7. Data Computations and Data Imputations
13.7.1. Time to Confirmed Perceptible and Meaningful Pain Relief
The time to meaningful pain relief is defined as the time (in minutes) elapsed from dosing until 
the subject stopped the second stopwatc h.  Time to confirmed perceptible pain relief is defined 
as the time (in minutes) to perceptible pain relief as indicated on the first stopwatch , provided 
that the subject also stopped the second stopwatch indicating meaningful pain relief.
For these relief variables, subjects who do not have relief by 4hours, who take re scue 
medication before having relief, or who discontinue before having relief will have their time of 
relief set to 4hours and be censored at 4hours.
13.7.2. Endpoints Relating to Pain Intensity and Pain Relief
The pain intensity difference (PID) at each time point will be derived by subtracting the pain 
intensity from the baseline pain intensity.  A higher value is indicative of a greater 
improvement.
Time-weighted sum of the pain intensity difference scores (SP ID)willbederived byfirst 
multipl ying ea ch PID score b y the time from the previous time point, and adding them together 
for each scheduled time point from 0 -4hours. T ime-weighted total pain relief (TOTPAR) for 
each specified interval will be similarly derived.
Pain intensity and pain relief rat ings provided at times differing from the intended times by  
more than ± 5 minutes for the scores up to 90 minutes pos t-dose, and bymore than ± 15 
minutes for the remaining measurements will be estimated by linear interpolation.  For subjects 
who use rescue medication, the last reported pain score or baseline pain score, whichever is 
worse, will be carried forward to the remaining time points; pain relief scores after rescue 
medication will be set to zero. For subjects who discontinue the study early,the same 
imputation approach will be used.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
4913.8. Analysis Methods
13.8.1. Time to Confirmed Perceptible and Meaningful Relief
Time to confirmed perceptible pain relief (TCPR) and time to meaningful pain relief (TMPR) 
will be anal yzed using survival data analy sis. The survival function (cumulative proportions of 
subjects with pain relief at each time point) and the median survival time will be estimated by  
the Kaplan- Meier method for each treatment. The median survival times forthe active 
treatments will be comp ared using the bootstrap re -sampling method ,and the survival 
functions of the active treatments will be compared with the survival function of placebo using 
the Wilcoxon test. The median survival time is chosen as an endpoint for evaluating the effect 
of time to onset, and the bootstrap method is an appropriate method for comparing the median 
survival time when the survival functions are non- proportional.
13.8.2. Earliest Statistically Significant Separation of  and Placebo on
Percentage of Subjects with Confirmed Perceptible Relief
The earliest time of separation between  and placebo will be established by  
comparing the percentage of subjects with confirmed perceptible pain relief starting from 30 
minutes to successive earlier minutes in on e minute increments, until statistical significance is 
no longer achieved. The dichotomized response will be analyzed using logistic regression 
analysis.
13.8. 3. Percentage of Subjects with Meaningful Pain Relief at 35, 40, and 45 minutes
The percentage of subjects with meaningful pain relief at 35, 40 and 45 minutes will be 
analyzed using logistic regression analysisand compared between  and ACM at each 
time point .
13.8. 4. Percentage of Subjects with Confirmed Perceptible Pain Relief at15, 20, an d 
25 minutes
The percentage of subjects with confirmed perceptible pain relief at 15, 20 and 25 minutes will 
be anal yzed using logistic regression analysisat each time point.
13.8. 5. SPID0 -4 and TOTPAR0-4
SPID0-4 and TOTPAR0-4 will eachbe ana lyzedwith a n ana lysis of variance with baseline 
pain (moderate or severe) score and treatment group in the model using imputation methods 
defined in Data Imputations Section 13.7.2. 
13.8. 6. PID and PAR at each Time
PIDand PAR will be an alyzed at each time point with an ana lysis of variance with baseline 
pain score (moderate or severe) and treatment group in the model.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
5013.8. 7. Time to Rescue
Time to first use of rescue medication will be measured as the elapsed time from when the 
investig ational product was given until the time rescue medication was first given . Subjects 
who discontinue from the study before 4 hours, but do not use rescue medication, will be 
censored at the time of discontinuation. Subjects who do not use rescue medication during the 
4-hour studyperiod will have their time to rescue set to 4hours and becensored at.4 hours.
Kaplan -Meier estimates of cumulative percentage of subjects rescuing will be presented b y 
treatment group in tabular and graphical formats. The survival functions will be compared 
between the treatment groups using the Wilcoxon test.
13.8. 8. Subject Global Evaluation
Subject Global Evaluation will be ana lyzed using ananalysis of variance with treatment and 
categorical baseline pain as factor s. Missing data will not be imputed for this variable . Pairwise 
comparisons specified in Section 13.6 willbe anal yzed.
13.8.9 . Subgroup Analyses
Time to confirmed perceptible relief and time to meaningful relief will be anal yzed based on 
the following subgroups: age group (<18 years, ≥18years), gender , race (white, non -white) and 
baseline categorical pain (moderate, severe). The survival function and the median survival 
time will be estimated by the Kaplan -Meier method within each sub group. 
13.9. Safety Analysis
Thesafetyanalysis will be based on the saf etyanalysis set.
13.9.1. Adverse Events
Treatment -emergent AEs are those with a start date and time at or after the time of study  drug 
administration. All summaries described belo w are for treatment -emergent AEs except where 
noted. Non treatment -emergent AEs will be provided in a listing.
The number and percentage of subjects experiencing AEs willbetabulated bytreatment, 
system organ class and preferred term using the MedDRA coding dictionary . The number and 
percentage of subjects experiencing treatment -related AEs will also be presented by system 
organ class and preferred term. Treatment -related AEs will include events marked as being at 
least possibly related tostudy treatment .The n umber and percentage of subjects with AEs will 
be presented by severit y. Subjects will be counted only once foreach system organ class and 
preferred term b y selecting the most severe event. The number of subjects with the most 
commonly reported adv erse events (those reported by 5% or more in a ny one treatment group) 
will be summarized by treatment, s ystem organ class and preferred term. The number of 
subjects with adverse events will also be summarized by  demographic characteristics: age 
group (<18 years, ≥18years),gender , andrace.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
51The number and percentage of subjects experiencing SAEs or who discontinued the study due 
to an AE will be presented by system organ class and preferred term. These displa ys will 
include all AEs, not just treatment- emergent AEs.
14. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS
The sponsor should ensure that it is specified in the protocol or written agreement that the 
investigator(s)/institutions(s) will permit study related monitoring, audits, IRB/IEC review, and 
regulatory inspe ction(s) byproviding access to the source data/documents.
14.1. Study Monitoring
Before an investigational site can enter a subject into the study, a representative of Johnson & 
Johnson will visit the investigational stu dysiteto:
Determine the adequacy of the facilities
Discuss with the investigator(s) and other site personnel their responsibilities with 
regard to protocol adherence as well as the stud yand monitoring responsibilities of 
Johnson & Johnson or its representatives.  These responsibiliti es will be documented in 
a Clinical Study Agreement between Johnson & Johnson and the investigator. During
the stud y, a monitor from Johnson & Johnson or representative will have regular 
contacts with the investigational site, for th e following:
Provide inf ormation and support to the investigator(s)
Confirm that facilities remain acceptable
Confirm that the investigational team is adhering to the protocol, that data are being 
accurate ly recorded in the CRF , and that investigational product a ccountability checks 
are being performed
Perform source data verification. This includes a comparison of the data in the case 
report forms with the subject’s medical records at the hospital or practice, and other 
records relevant to the study . This will require direct a ccess to all original records for 
each subject (e.g., clinic charts).
Record and report all protocol deviations not previously sent to Johnson & Johnson.
Confirm AEs and SAEs have been properly documented on CRFs and confirm an y
SAEs ha ve been forwarded to Johnson & Johnson and those SAEs that met criteria for 
reporting have been forwarded to the IR B/IEC.
The monitor will be available between visits if the investigator(s) or other staff needs 
information or study-related directi on.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
5214.2. Audits and Inspections
Authorized representatives of Johnson & Johnso n, a regulatory authorit y, an Independent 
Ethics Committee or an Institutional Review Board may visit the site to perform audits or 
inspections, including source data verification. The p urpose of a Johnson & Johnson audit or 
inspection is to s ystematically and independently examine allstudy-related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurate lyreported acco rding to the protocol, ICH/GCP and any applicable 
regulatory requirements. The investigator should contact their study contacts immediately if 
contacted by a regulatory agency about an inspection.
14.3. Institutional Review Board (IRB)/Independent Ethics C ommittee 
(IEC)
The Principal Investigator must obtain IRB/I ECapproval for the investigation. I nitial IRB/ IEC
approval of the protocol and all materials approved bythe IRB/IEC forthisstudy, including 
the subject consent form and recruitment materials, m ust be maintained in the Site Master File 
bytheInvestigator and made available for inspection.
15. QUALITY CONTROL AND QUALITY ASSURANCE
During stu dy conduct, the Sponsor or its agent will conduct periodic monitoring visits to 
oversee the progress of a c linical trial, and to ensure that it is conducted, recorded, and reported 
in accordance with the protocol, Standard Operating Procedures, ICH/GCP, and the applicable 
regulatory requirement(s).
The monitors may review source documents to confirm that the da ta recorded on CRFs is 
accurat e. The investigator and institution will allow the Sponsor monitors or its agents and 
appropriate regulatory authorities direct access to source documents to perform this 
verification.
The study sitemaybe subject to review bytheIRB/IEC, and/or to quality assurance audits 
performed by the Sponsor, and/or to inspection by appropriate regulatory authorities.
In the event that the study site is notified of a regulatory inspection, the Sponsor must be 
notified immediately.
Itis important that the investiga tor(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
5316. DATA HANDLING AND R ECORDKEEPING
16.1. Case Report Form s/ Electronic Data Record
All data will be collected on source documents first and then recorded in an Electronic Data 
Capture (EDC) sy stem. The EDC s ystem is the database where pertinent study data are 
collected such as demograph y, subject randomization, efficacy assessments, adverse events, 
and subject disposition. EDC CRFs should be completed for each included subject. The 
completed pages of the EDC system are the sole propert y of the Sponsor and should not be 
made available in a nyform to third parties, except for authorized representatives of the 
Sponsor or appropriate regulatory authorities, without written permission from the Sponsor .
It is the Investigator's responsibility to ensure completion and to review and approve all 
inform ation captured in the EDC. The subject ’s data in the EDC s ystem must be electronicall y
signed by the Investigator. These signatures serve to attest that the information contained in the 
EDC system is true. At all times, the Investigator has final personal responsibility for the 
accuracy and authentici ty of all clinical and labor atory  data entered in the EDC. Subject source 
documents are the Investigator's/p hysician's subject records maintained at the study site. In 
cases where the source documents are the hospital or the phy sician's chart, the information 
collected in the EDC must match those charts. All final data recorded in EDC system will be 
copied i nto files and kept by the Sponsor . A co pyof these files will also be kept at the clinical 
site. All data provided in the CRF m ust be supported by  source document. For this stud y, the 
Sponsor will provide specific worksheets (NRS scales /Subject Global Evaluation) to serve as 
source document tools to collect pain intensity , pain relief, and global evaluation.
16.2. Record Retention
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the investigator 
agrees to keep records including the identit y of all participating subjects (sufficient information 
to link records, e.g., CRFs and hospital records), all ori ginal signed informed cons ent forms, 
copies of all CRFs, SAE report forms, source documents, and detailed rec ords of treatment 
disposition. The records should be retained b ythe investigator according to I CH guidelines, 
local regulations, or as specified in the Clinical Study  Agree ment, whichever is longer.
If the investigator relocates, retires, or for a ny reason withdraws from the stud y, the Sponsor 
should be prospective ly notified. The study records must be transferred to an acceptable 
designee, such as another investigator, an other i nstitution, or to the Sponsor. The investigator 
must obtain Sponsor's written permission before disposing of an yrecords, even if retent ion 
requirements have been met.
17. SPONSOR DISCONTINUA TION CRITERIA
Premature terminatio n of this clinical study mayoccur because of a regulatory authority  
decision, change in opinion of the IRB/IEC, drug safe ty problems, or at the discretion of the 

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
54sponsor. In addition, the sponsor retains the right to discontinue development of the  
500 mg atany time.
If a study isprematurely terminated or discontinued, the sponsor will promptly notify the 
investigator. After notification, the investigator must contact all participat ing subjects within 
two weeks. All study materi als must be collec ted and all CRFs completed t o the greatest extent 
possible.
18. PUBLICATION POLICY
Publication of study results bythe investigator is discussed in the Clinical Study Agreement, as 
appropriate. Results from this study maybe published in the form of oral o r written 
presentations at scientific meetings or as one or more pee r-reviewed journal articles. In these 
cases, no information on indivi dual subjects will be revealed.
19. LIST OF REFERENCES
1. Averbuch M, Katzper M. Baseline pain and response to analgesic m edications in the 
postsur gerydental pain model. JClin Pharmacol 2000;40:133 -137.
2.Cooper SA. Singl e-dose analgesic studies: the upside and downside of assay  sensitivit y. 
In: Max M, Portenoy R, Laska E, eds. Advances in pain research and thera py. Vol 18. 
New York, NY: Raven Press, L td., 1991:117-24.
3.Data o n file for “Simulation based sample size and power for dental 3 study” , McNeil 
Consumer Healthcare, Fort Washington, PA, 201 7.
4.Wiens, BL . A fixed sequence Bonferroni procedure for testing multiple endpoin ts. 
Pharmaceutical Statistics 2003; 2:211-215.

Protocol:CO- 170317095828 -PACT
FINAL 16May2017
5520. APPENDICES
APPENDIX 1: PAIN RATING SCALES / CATEGORICAL PAIN INTENSITY 
SCALE
Finish the statement “Mypain atthistime is”bychecking the appropriate box.
No Pain (0)
Mild Pain (1) Mo derate P ain (2) Severe Pain (3)
0-10 PAIN INTENSITY -NUMERICAL RATING SCALE (P I-NRS)
Circle the number that best represents your pain.
No pain   0  1  2  3  4  5  6  7  8  9  10   Very severe pain
0-10 PAIN RELIEF – NUMERICAL RATING SCALE (PR- NRS)
Circle the numb er that shows your amount of pain relief.
No relief   0  1  2  3  4  5  6  7  8  9  10   Complete relief
APPENDIX 2: SUBJECT GLOBAL EVALUATION
How would youratethestudy medication you received as a pain -reliever?
Poor (0) 
Fair (1) 
Good (2)
VeryGood ( 3) 
Excellent (4)
